Filomena Iannuzzi

Dr. Filomena Iannuzzi

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2018 in Current Alzheimer Research
Verified
Journal Article
Closed access
SMSerena Marcelli
Serena Marcelli
MCMassimo Corbo
Massimo Corbo
FIFilomena Iannuzzi
Filomena Iannuzzi
LNLucia Negri
Lucia Negri
FBFabio Blandini
Fabio Blandini
MFMarco Feligioni
Marco Feligioni
Background: Alzheimer's disease (AD) is a neurodegenerative disorder recognized as the most common cause of chronic dementia among the ageing population. AD is histopathologically characterized by progressive loss of neurons and deposits of insoluble proteins, primarily composed of amyloid-β pelaques and neurofibrillary tangles (NFTs). Methods: Several molecular processes contribute to the formation of AD cellular hallmarks. Among them, post-translational modifications (PTMs) represent an attractive mechanism underlying the formation of covalent bonds between chemical groups/peptides to target proteins, which ultimately result modified in their function. Most of the proteins related to AD undergo PTMs. Several recent studies show that AD-related proteins like APP, Aβ, tau, BACE1 undergo post-translational modifications. The effect of PTMs contributes to the normal function of cells, although aberrant protein modification, which may depend on many factors, can drive the onset or support the development of AD. Results: Here we will discuss the effect of several PTMs on the functionality of AD-related proteins potentially contributing to the development of AD pathology. Conclusion: We will consider the role of Ubiquitination, Phosphorylation, SUMOylation, Acetylation and Nitrosylation on specific AD-related proteins and, more interestingly, the possible interactions that may occur between such different PTMs.

22 April 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
FFFulvio Florenzano
Fulvio Florenzano
VCVeronica Corsetti
Veronica Corsetti
GCGabriele Ciasca
Gabriele Ciasca
MCMaria Teresa Ciotti
Maria Teresa Ciotti
APAnna Pittaluga
Anna Pittaluga
Giuseppina AmadoroGiuseppina Amadoro
Giuseppina Amadoro
The largest part of tau secreted from AD nerve terminals and released in cerebral spinal fluid (CSF) is C-terminally truncated, soluble and unaggregated supporting potential extracellular role(s) of NH2-derived fragments of protein on synaptic dysfunction underlying neurodegenerative tauopathies, including Alzheimer’s disease (AD). Here we show that sub-toxic doses of extracellular-applied human NH2tau 26-44 (aka NH2htau) -which is the minimal active moiety of neurotoxic 20-22kDa peptide accumulating in vivo at AD synapses and secreted into parenchyma- acutely provokes presynaptic deficit in K+-evoked glutamate release on hippocampal synaptosomes along with alteration in local Ca2+ dynamics. Neuritic dystrophy, microtubules breakdown, deregulation in presynaptic proteins and loss of mitochondria located at nerve endings are detected in hippocampal cultures only after prolonged exposure to NH2htau. The specificity of these biological effects is supported by the lack of any significant change, either on neuronal activity or on cellular integrity, shown by administration of its reverse sequence counterpart which behaves as an inactive control, likely due to a poor conformational flexibility which makes it unable to dynamically perturb biomembrane-like environments. Our results demonstrate that one of the AD-relevant, soluble and secreted N-terminally truncated tau forms can early contribute to pathology outside of neurons causing alterations in synaptic activity at presynaptic level, independently of overt neurodegeneration.

1 January 2017 in Neural Plasticity
Verified
Journal Article
Open access
PDF file
AZAlen Zollo
Alen Zollo
ZAZoe Allen
Zoe Allen
HRHelle F. Rasmussen
Helle F. Rasmussen
FIFilomena Iannuzzi
Filomena Iannuzzi
YSYichen Shi
Yichen Shi
CMCarmela Matrone
Carmela Matrone
Alzheimer’s disease (AD) is the most common form of dementia in the elderly; important risk factors are old age and inheritance of the apolipoprotein E4 (APOE4) allele. Changes in amyloid precursor protein (APP) binding, trafficking, and sorting may be important AD causative factors. Secretase-mediated APP cleavage produces neurotoxic amyloid-beta (Aβ) peptides, which form lethal deposits in the brain. In vivo and in vitro studies have implicated sortilin-related receptor (SORL1) as an important factor in APP trafficking and processing. Recent in vitro evidence has associated the APOE4 allele and alterations in the SORL1 pathway with AD development and progression. Here, we analyzed SORL1 expression in neural stem cells (NSCs) from AD patients carrying null, one, or two copies of the APOE4 allele. We show reduced SORL1 expression only in NSCs of a patient carrying two copies of APOE4 allele with increased Aβ/SORL1 localization along the degenerated neurites. Interestingly, SORL1 binding to APP was largely compromised; this could be almost completely reversed by γ-secretase (but not β-secretase) inhibitor treatment. These findings may yield new insights into the complex interplay of SORL1 and AD pathology and point to NSCs as a valuable tool to address unsolved AD-related questions in vitro.

21 July 2017 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
RBRaffaella Bucci
Raffaella Bucci
PDPriyadip Das
Priyadip Das
FIFilomena Iannuzzi
Filomena Iannuzzi
MFMarco Feligioni
Marco Feligioni
RGRaffaella Gandolfi
Raffaella Gandolfi
sara pellegrinosara pellegrino
sara pellegrino
The development of molecular carriers able to carry molecules directly into the cell is an area of intensive research. Cationic nanoparticles are effective delivery systems for several classes of molecules, such as anticancer agents, oligonucleotides and antibodies. Indeed, a cationic charge on the outer surface allows a rapid cellular uptake together with the possibility of carrying negatively charged molecules. In this work, we studied the self-assembly of an ultra-short ααβ-tripeptide containing an L-Arg–L-Ala sequence and an unnatural fluorine substituted β2,3-diaryl-amino acid. The presence of the unnatural β2,3-diaryl-amino acid allowed us to obtain a protease stable sequence. Furthermore, an arginine guanidinium group triggered the formation of spherical assemblies that were able to load small molecules and enter cells. These spherical architectures, thus, represent interesting candidates for the delivery of exogenous entities directly into cells.

30 July 2020 in Cells
Verified
Journal Article
Open access
PDF file
FIFilomena Iannuzzi
Filomena Iannuzzi
RSRossana Sirabella
Rossana Sirabella
Nadia CanuNadia Canu
Nadia Canu
TMThorsten Jürgen Maier
Thorsten Jürgen Maier
LALUCIO ANNUNZIATO
LUCIO ANNUNZIATO
CMCarmela Matrone
Carmela Matrone
Alzheimer’s disease (AD) is an incurable neurodegenerative disorder with a few early detection strategies. We previously proposed the amyloid precursor protein (APP) tyrosine 682 (Tyr682) residue as a valuable target for the development of new innovative pharmacologic or diagnostic interventions in AD. Indeed, when APP is phosphorylated at Tyr682, it is forced into acidic neuronal compartments where it is processed to generate neurotoxic amyloid β peptides. Of interest, Fyn tyrosine kinase (TK) interaction with APP Tyr682 residue increases in AD neurons. Here we proved that when Fyn TK was overexpressed it elicited APP Tyr682 phosphorylation in neurons from healthy donors and promoted the amyloidogenic APP processing with Aβ peptides accumulation and neuronal death. Phosphorylation of APP at Tyr (pAPP-Tyr) increased in neurons of AD patients and AD neurons that exhibited high pAPP-Tyr also had higher Fyn TK activity. Fyn TK inhibition abolished the pAPP-Tyr and reduced Aβ42 secretion in AD neurons. In addition, the multidomain adaptor protein Fe65 controlled the Fyn-mediated pAPP-Tyr, warranting the possibility of targeting the Fe65-APP-Fyn pathway to develop innovative strategies in AD. Altogether, these results strongly emphasize the relevance of focusing on pAPP Tyr682 either for diagnostic purposes, as an early biomarker of the disease, or for pharmacological targeting, using Fyn TKI.

13 October 2016 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SMSerena Marcelli
Serena Marcelli
EFElena Ficulle
Elena Ficulle
FIFilomena Iannuzzi
Filomena Iannuzzi
EKEnikö Kövari
Enikö Kövari
RNRobert Nisticò
Robert Nisticò
MFMarco Feligioni
Marco Feligioni